nodes	percent_of_prediction	percent_of_DWPC	metapath
Topiramate—CYP2C19—Vismodegib—skin cancer	0.0814	0.295	CbGbCtD
Topiramate—CYP3A4—Temozolomide—skin cancer	0.0567	0.206	CbGbCtD
Topiramate—CYP3A4—Imiquimod—skin cancer	0.0567	0.206	CbGbCtD
Topiramate—CYP3A4—Vismodegib—skin cancer	0.0393	0.143	CbGbCtD
Topiramate—CYP3A4—Vemurafenib—skin cancer	0.0311	0.113	CbGbCtD
Topiramate—GRIA4—nerve—skin cancer	0.019	0.101	CbGeAlD
Topiramate—GRIK1—nerve—skin cancer	0.0167	0.0885	CbGeAlD
Topiramate—GRIA3—nerve—skin cancer	0.0155	0.0822	CbGeAlD
Topiramate—CA6—ear—skin cancer	0.0131	0.0698	CbGeAlD
Topiramate—CYP3A4—Docetaxel—skin cancer	0.0107	0.0387	CbGbCtD
Topiramate—GRIA1—nerve—skin cancer	0.00827	0.0439	CbGeAlD
Topiramate—CA6—hair follicle—skin cancer	0.00692	0.0368	CbGeAlD
Topiramate—GRIK2—nerve—skin cancer	0.00593	0.0315	CbGeAlD
Topiramate—GRIK3—mammalian vulva—skin cancer	0.00581	0.0309	CbGeAlD
Topiramate—GRIK4—head—skin cancer	0.0057	0.0303	CbGeAlD
Topiramate—GRIK3—female reproductive system—skin cancer	0.00498	0.0264	CbGeAlD
Topiramate—GRIA4—head—skin cancer	0.00451	0.0239	CbGeAlD
Topiramate—CA1—nerve—skin cancer	0.00439	0.0233	CbGeAlD
Topiramate—GRIK5—head—skin cancer	0.00416	0.0221	CbGeAlD
Topiramate—GRIK3—head—skin cancer	0.00416	0.0221	CbGeAlD
Topiramate—GRIK1—head—skin cancer	0.00395	0.021	CbGeAlD
Topiramate—GRIA3—head—skin cancer	0.00367	0.0195	CbGeAlD
Topiramate—CA5A—female reproductive system—skin cancer	0.00364	0.0194	CbGeAlD
Topiramate—CA4—nerve—skin cancer	0.00343	0.0182	CbGeAlD
Topiramate—GRIK5—lymph node—skin cancer	0.00291	0.0155	CbGeAlD
Topiramate—GRIK3—lymph node—skin cancer	0.00291	0.0155	CbGeAlD
Topiramate—CA2—hair follicle—skin cancer	0.00238	0.0127	CbGeAlD
Topiramate—CA12—connective tissue—skin cancer	0.00223	0.0119	CbGeAlD
Topiramate—CA9—female reproductive system—skin cancer	0.00213	0.0113	CbGeAlD
Topiramate—GRIA1—head—skin cancer	0.00196	0.0104	CbGeAlD
Topiramate—CA6—head—skin cancer	0.00196	0.0104	CbGeAlD
Topiramate—CA4—nipple—skin cancer	0.00195	0.0104	CbGeAlD
Topiramate—CA4—neck—skin cancer	0.00193	0.0102	CbGeAlD
Topiramate—CA5B—mammalian vulva—skin cancer	0.00165	0.00876	CbGeAlD
Topiramate—CA2—nipple—skin cancer	0.00162	0.00858	CbGeAlD
Topiramate—CA2—neck—skin cancer	0.0016	0.00849	CbGeAlD
Topiramate—CA12—female reproductive system—skin cancer	0.00157	0.00836	CbGeAlD
Topiramate—GRIA2—head—skin cancer	0.00156	0.00828	CbGeAlD
Topiramate—SCN1A—head—skin cancer	0.00142	0.00755	CbGeAlD
Topiramate—CA5B—female reproductive system—skin cancer	0.00141	0.0075	CbGeAlD
Topiramate—GRIK2—head—skin cancer	0.00141	0.00748	CbGeAlD
Topiramate—CA12—head—skin cancer	0.00132	0.00699	CbGeAlD
Topiramate—CA1—lymphoid tissue—skin cancer	0.00129	0.00687	CbGeAlD
Topiramate—CA1—female reproductive system—skin cancer	0.00125	0.00662	CbGeAlD
Topiramate—CA5B—head—skin cancer	0.00118	0.00627	CbGeAlD
Topiramate—CA2—connective tissue—skin cancer	0.00115	0.00609	CbGeAlD
Topiramate—SCN5A—head—skin cancer	0.00114	0.00607	CbGeAlD
Topiramate—GABRB2—head—skin cancer	0.00111	0.00589	CbGeAlD
Topiramate—GABRG2—head—skin cancer	0.00111	0.00589	CbGeAlD
Topiramate—CA2—epithelium—skin cancer	0.00109	0.00578	CbGeAlD
Topiramate—CA1—head—skin cancer	0.00104	0.00553	CbGeAlD
Topiramate—CA2—skin of body—skin cancer	0.00104	0.0055	CbGeAlD
Topiramate—GABRA1—head—skin cancer	0.000979	0.0052	CbGeAlD
Topiramate—CA4—female reproductive system—skin cancer	0.000975	0.00518	CbGeAlD
Topiramate—CA2—mammalian vulva—skin cancer	0.000944	0.00501	CbGeAlD
Topiramate—CA2—lymphoid tissue—skin cancer	0.000838	0.00445	CbGeAlD
Topiramate—CA5B—lymph node—skin cancer	0.000826	0.00439	CbGeAlD
Topiramate—CA4—head—skin cancer	0.000815	0.00433	CbGeAlD
Topiramate—CA2—female reproductive system—skin cancer	0.000809	0.00429	CbGeAlD
Topiramate—CA1—lymph node—skin cancer	0.00073	0.00388	CbGeAlD
Topiramate—CA2—head—skin cancer	0.000675	0.00359	CbGeAlD
Topiramate—CA4—lymph node—skin cancer	0.00057	0.00303	CbGeAlD
Topiramate—SCN1A—Interaction between L1 and Ankyrins—SCN10A—skin cancer	0.000527	0.0767	CbGpPWpGaD
Topiramate—CYP3A4—female reproductive system—skin cancer	0.000522	0.00277	CbGeAlD
Topiramate—CA2—lymph node—skin cancer	0.000473	0.00251	CbGeAlD
Topiramate—SCN5A—Interaction between L1 and Ankyrins—SCN10A—skin cancer	0.000371	0.0539	CbGpPWpGaD
Topiramate—Abdominal pain upper—Docetaxel—skin cancer	0.000345	0.000652	CcSEcCtD
Topiramate—Orthostatic hypotension—Docetaxel—skin cancer	0.000345	0.000652	CcSEcCtD
Topiramate—Rash—Vemurafenib—skin cancer	0.000344	0.000651	CcSEcCtD
Topiramate—Mental disorder—Temozolomide—skin cancer	0.000344	0.00065	CcSEcCtD
Topiramate—Dermatitis—Vemurafenib—skin cancer	0.000344	0.00065	CcSEcCtD
Topiramate—Hypersensitivity—Imiquimod—skin cancer	0.000343	0.000648	CcSEcCtD
Topiramate—Headache—Vemurafenib—skin cancer	0.000342	0.000646	CcSEcCtD
Topiramate—Malnutrition—Temozolomide—skin cancer	0.000342	0.000646	CcSEcCtD
Topiramate—Erythema—Temozolomide—skin cancer	0.000342	0.000646	CcSEcCtD
Topiramate—Breast disorder—Docetaxel—skin cancer	0.000341	0.000645	CcSEcCtD
Topiramate—Discomfort—Bleomycin—skin cancer	0.000341	0.000644	CcSEcCtD
Topiramate—Malaise—Dactinomycin—skin cancer	0.000341	0.000644	CcSEcCtD
Topiramate—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.00034	0.000642	CcSEcCtD
Topiramate—Toxic epidermal necrolysis—Docetaxel—skin cancer	0.00034	0.000642	CcSEcCtD
Topiramate—Leukopenia—Dactinomycin—skin cancer	0.000338	0.000639	CcSEcCtD
Topiramate—Nasopharyngitis—Docetaxel—skin cancer	0.000337	0.000638	CcSEcCtD
Topiramate—Dysgeusia—Temozolomide—skin cancer	0.000335	0.000633	CcSEcCtD
Topiramate—Asthenia—Imiquimod—skin cancer	0.000334	0.000631	CcSEcCtD
Topiramate—Confusional state—Bleomycin—skin cancer	0.000333	0.00063	CcSEcCtD
Topiramate—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000333	0.000629	CcSEcCtD
Topiramate—Oedema—Bleomycin—skin cancer	0.000331	0.000625	CcSEcCtD
Topiramate—Back pain—Temozolomide—skin cancer	0.000331	0.000625	CcSEcCtD
Topiramate—Pruritus—Imiquimod—skin cancer	0.000329	0.000623	CcSEcCtD
Topiramate—Infection—Bleomycin—skin cancer	0.000328	0.000621	CcSEcCtD
Topiramate—Dysphagia—Docetaxel—skin cancer	0.000326	0.000617	CcSEcCtD
Topiramate—Nausea—Vemurafenib—skin cancer	0.000324	0.000613	CcSEcCtD
Topiramate—Thrombocytopenia—Bleomycin—skin cancer	0.000324	0.000612	CcSEcCtD
Topiramate—Vision blurred—Temozolomide—skin cancer	0.000322	0.000609	CcSEcCtD
Topiramate—Myalgia—Dactinomycin—skin cancer	0.000322	0.000608	CcSEcCtD
Topiramate—Tremor—Temozolomide—skin cancer	0.00032	0.000605	CcSEcCtD
Topiramate—Alopecia—Fluorouracil—skin cancer	0.00032	0.000604	CcSEcCtD
Topiramate—Diarrhoea—Imiquimod—skin cancer	0.000318	0.000602	CcSEcCtD
Topiramate—Discomfort—Dactinomycin—skin cancer	0.000318	0.000601	CcSEcCtD
Topiramate—Angina pectoris—Docetaxel—skin cancer	0.000318	0.000601	CcSEcCtD
Topiramate—Ill-defined disorder—Temozolomide—skin cancer	0.000317	0.000599	CcSEcCtD
Topiramate—Anaemia—Temozolomide—skin cancer	0.000316	0.000597	CcSEcCtD
Topiramate—Anorexia—Bleomycin—skin cancer	0.000315	0.000596	CcSEcCtD
Topiramate—Erythema—Fluorouracil—skin cancer	0.000315	0.000595	CcSEcCtD
Topiramate—Agitation—Temozolomide—skin cancer	0.000314	0.000594	CcSEcCtD
Topiramate—Pancytopenia—Docetaxel—skin cancer	0.00031	0.000586	CcSEcCtD
Topiramate—Hypotension—Bleomycin—skin cancer	0.000309	0.000584	CcSEcCtD
Topiramate—Oedema—Dactinomycin—skin cancer	0.000308	0.000583	CcSEcCtD
Topiramate—Malaise—Temozolomide—skin cancer	0.000308	0.000583	CcSEcCtD
Topiramate—Dizziness—Imiquimod—skin cancer	0.000308	0.000582	CcSEcCtD
Topiramate—Vertigo—Temozolomide—skin cancer	0.000307	0.00058	CcSEcCtD
Topiramate—Infection—Dactinomycin—skin cancer	0.000306	0.000579	CcSEcCtD
Topiramate—Leukopenia—Temozolomide—skin cancer	0.000306	0.000578	CcSEcCtD
Topiramate—Neutropenia—Docetaxel—skin cancer	0.000305	0.000577	CcSEcCtD
Topiramate—Palpitations—Temozolomide—skin cancer	0.000302	0.000571	CcSEcCtD
Topiramate—Thrombocytopenia—Dactinomycin—skin cancer	0.000302	0.000571	CcSEcCtD
Topiramate—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000301	0.00057	CcSEcCtD
Topiramate—Cough—Temozolomide—skin cancer	0.000298	0.000564	CcSEcCtD
Topiramate—Paraesthesia—Bleomycin—skin cancer	0.000297	0.000561	CcSEcCtD
Topiramate—Weight increased—Docetaxel—skin cancer	0.000297	0.000561	CcSEcCtD
Topiramate—Vision blurred—Fluorouracil—skin cancer	0.000297	0.000561	CcSEcCtD
Topiramate—Convulsion—Temozolomide—skin cancer	0.000296	0.00056	CcSEcCtD
Topiramate—Vomiting—Imiquimod—skin cancer	0.000296	0.000559	CcSEcCtD
Topiramate—Weight decreased—Docetaxel—skin cancer	0.000295	0.000558	CcSEcCtD
Topiramate—Hypertension—Temozolomide—skin cancer	0.000295	0.000558	CcSEcCtD
Topiramate—Dyspnoea—Bleomycin—skin cancer	0.000295	0.000557	CcSEcCtD
Topiramate—Anorexia—Dactinomycin—skin cancer	0.000294	0.000556	CcSEcCtD
Topiramate—Rash—Imiquimod—skin cancer	0.000293	0.000555	CcSEcCtD
Topiramate—Dermatitis—Imiquimod—skin cancer	0.000293	0.000554	CcSEcCtD
Topiramate—Pneumonia—Docetaxel—skin cancer	0.000293	0.000553	CcSEcCtD
Topiramate—Headache—Imiquimod—skin cancer	0.000292	0.000551	CcSEcCtD
Topiramate—Anaemia—Fluorouracil—skin cancer	0.000291	0.00055	CcSEcCtD
Topiramate—Myalgia—Temozolomide—skin cancer	0.000291	0.00055	CcSEcCtD
Topiramate—Arthralgia—Temozolomide—skin cancer	0.000291	0.00055	CcSEcCtD
Topiramate—Infestation NOS—Docetaxel—skin cancer	0.000291	0.00055	CcSEcCtD
Topiramate—Infestation—Docetaxel—skin cancer	0.000291	0.00055	CcSEcCtD
Topiramate—Anxiety—Temozolomide—skin cancer	0.00029	0.000548	CcSEcCtD
Topiramate—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000289	0.000546	CcSEcCtD
Topiramate—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000288	0.000545	CcSEcCtD
Topiramate—Discomfort—Temozolomide—skin cancer	0.000287	0.000543	CcSEcCtD
Topiramate—Decreased appetite—Bleomycin—skin cancer	0.000287	0.000543	CcSEcCtD
Topiramate—Renal failure—Docetaxel—skin cancer	0.000286	0.00054	CcSEcCtD
Topiramate—Neuropathy peripheral—Docetaxel—skin cancer	0.000285	0.000539	CcSEcCtD
Topiramate—Dry mouth—Temozolomide—skin cancer	0.000285	0.000538	CcSEcCtD
Topiramate—Stomatitis—Docetaxel—skin cancer	0.000283	0.000536	CcSEcCtD
Topiramate—Pain—Bleomycin—skin cancer	0.000283	0.000535	CcSEcCtD
Topiramate—Conjunctivitis—Docetaxel—skin cancer	0.000283	0.000534	CcSEcCtD
Topiramate—Leukopenia—Fluorouracil—skin cancer	0.000282	0.000533	CcSEcCtD
Topiramate—Confusional state—Temozolomide—skin cancer	0.000281	0.000532	CcSEcCtD
Topiramate—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000281	0.000531	CcSEcCtD
Topiramate—Oedema—Temozolomide—skin cancer	0.000279	0.000527	CcSEcCtD
Topiramate—Infection—Temozolomide—skin cancer	0.000277	0.000524	CcSEcCtD
Topiramate—Nausea—Imiquimod—skin cancer	0.000276	0.000523	CcSEcCtD
Topiramate—Epistaxis—Docetaxel—skin cancer	0.000274	0.000519	CcSEcCtD
Topiramate—Nervous system disorder—Temozolomide—skin cancer	0.000274	0.000517	CcSEcCtD
Topiramate—Thrombocytopenia—Temozolomide—skin cancer	0.000273	0.000516	CcSEcCtD
Topiramate—Convulsion—Fluorouracil—skin cancer	0.000273	0.000516	CcSEcCtD
Topiramate—Feeling abnormal—Bleomycin—skin cancer	0.000272	0.000515	CcSEcCtD
Topiramate—Agranulocytosis—Docetaxel—skin cancer	0.000271	0.000513	CcSEcCtD
Topiramate—Skin disorder—Temozolomide—skin cancer	0.000271	0.000512	CcSEcCtD
Topiramate—Hyperhidrosis—Temozolomide—skin cancer	0.00027	0.00051	CcSEcCtD
Topiramate—Chest pain—Fluorouracil—skin cancer	0.000268	0.000507	CcSEcCtD
Topiramate—Myalgia—Fluorouracil—skin cancer	0.000268	0.000507	CcSEcCtD
Topiramate—Decreased appetite—Dactinomycin—skin cancer	0.000268	0.000507	CcSEcCtD
Topiramate—Fatigue—Dactinomycin—skin cancer	0.000266	0.000503	CcSEcCtD
Topiramate—Anorexia—Temozolomide—skin cancer	0.000266	0.000503	CcSEcCtD
Topiramate—Discomfort—Fluorouracil—skin cancer	0.000265	0.000501	CcSEcCtD
Topiramate—Pain—Dactinomycin—skin cancer	0.000264	0.000499	CcSEcCtD
Topiramate—Urticaria—Bleomycin—skin cancer	0.000263	0.000497	CcSEcCtD
Topiramate—Haemoglobin—Docetaxel—skin cancer	0.000262	0.000496	CcSEcCtD
Topiramate—Rhinitis—Docetaxel—skin cancer	0.000262	0.000495	CcSEcCtD
Topiramate—Body temperature increased—Bleomycin—skin cancer	0.000261	0.000494	CcSEcCtD
Topiramate—Hepatitis—Docetaxel—skin cancer	0.000261	0.000494	CcSEcCtD
Topiramate—Haemorrhage—Docetaxel—skin cancer	0.000261	0.000494	CcSEcCtD
Topiramate—Hypoaesthesia—Docetaxel—skin cancer	0.00026	0.000491	CcSEcCtD
Topiramate—Confusional state—Fluorouracil—skin cancer	0.000259	0.00049	CcSEcCtD
Topiramate—Pharyngitis—Docetaxel—skin cancer	0.000259	0.00049	CcSEcCtD
Topiramate—Urinary tract disorder—Docetaxel—skin cancer	0.000258	0.000487	CcSEcCtD
Topiramate—Oedema peripheral—Docetaxel—skin cancer	0.000257	0.000486	CcSEcCtD
Topiramate—Oedema—Fluorouracil—skin cancer	0.000257	0.000486	CcSEcCtD
Topiramate—Connective tissue disorder—Docetaxel—skin cancer	0.000257	0.000485	CcSEcCtD
Topiramate—Urethral disorder—Docetaxel—skin cancer	0.000256	0.000484	CcSEcCtD
Topiramate—Infection—Fluorouracil—skin cancer	0.000255	0.000483	CcSEcCtD
Topiramate—Feeling abnormal—Dactinomycin—skin cancer	0.000254	0.00048	CcSEcCtD
Topiramate—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000254	0.00048	CcSEcCtD
Topiramate—GRIA4—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—skin cancer	0.000252	0.0367	CbGpPWpGaD
Topiramate—Insomnia—Temozolomide—skin cancer	0.000252	0.000477	CcSEcCtD
Topiramate—Gastrointestinal pain—Dactinomycin—skin cancer	0.000252	0.000477	CcSEcCtD
Topiramate—Nervous system disorder—Fluorouracil—skin cancer	0.000252	0.000476	CcSEcCtD
Topiramate—Thrombocytopenia—Fluorouracil—skin cancer	0.000252	0.000476	CcSEcCtD
Topiramate—Visual impairment—Docetaxel—skin cancer	0.000252	0.000476	CcSEcCtD
Topiramate—Tachycardia—Fluorouracil—skin cancer	0.000251	0.000474	CcSEcCtD
Topiramate—Paraesthesia—Temozolomide—skin cancer	0.00025	0.000474	CcSEcCtD
Topiramate—Dyspnoea—Temozolomide—skin cancer	0.000249	0.00047	CcSEcCtD
Topiramate—Somnolence—Temozolomide—skin cancer	0.000248	0.000469	CcSEcCtD
Topiramate—Erythema multiforme—Docetaxel—skin cancer	0.000247	0.000467	CcSEcCtD
Topiramate—Dyspepsia—Temozolomide—skin cancer	0.000246	0.000464	CcSEcCtD
Topiramate—CA9—HIF-1-alpha transcription factor network—PLIN2—skin cancer	0.000245	0.0356	CbGpPWpGaD
Topiramate—Anorexia—Fluorouracil—skin cancer	0.000245	0.000463	CcSEcCtD
Topiramate—Eye disorder—Docetaxel—skin cancer	0.000244	0.000461	CcSEcCtD
Topiramate—Abdominal pain—Dactinomycin—skin cancer	0.000244	0.000461	CcSEcCtD
Topiramate—Body temperature increased—Dactinomycin—skin cancer	0.000244	0.000461	CcSEcCtD
Topiramate—Hypersensitivity—Bleomycin—skin cancer	0.000244	0.000461	CcSEcCtD
Topiramate—Decreased appetite—Temozolomide—skin cancer	0.000242	0.000458	CcSEcCtD
Topiramate—Flushing—Docetaxel—skin cancer	0.000242	0.000458	CcSEcCtD
Topiramate—Cardiac disorder—Docetaxel—skin cancer	0.000242	0.000458	CcSEcCtD
Topiramate—Gastrointestinal disorder—Temozolomide—skin cancer	0.000241	0.000455	CcSEcCtD
Topiramate—Fatigue—Temozolomide—skin cancer	0.00024	0.000455	CcSEcCtD
Topiramate—Hypotension—Fluorouracil—skin cancer	0.00024	0.000454	CcSEcCtD
Topiramate—Constipation—Temozolomide—skin cancer	0.000239	0.000451	CcSEcCtD
Topiramate—Pain—Temozolomide—skin cancer	0.000239	0.000451	CcSEcCtD
Topiramate—Asthenia—Bleomycin—skin cancer	0.000237	0.000449	CcSEcCtD
Topiramate—Angiopathy—Docetaxel—skin cancer	0.000237	0.000448	CcSEcCtD
Topiramate—Immune system disorder—Docetaxel—skin cancer	0.000236	0.000446	CcSEcCtD
Topiramate—Mediastinal disorder—Docetaxel—skin cancer	0.000235	0.000445	CcSEcCtD
Topiramate—Chills—Docetaxel—skin cancer	0.000234	0.000443	CcSEcCtD
Topiramate—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000234	0.000443	CcSEcCtD
Topiramate—Pruritus—Bleomycin—skin cancer	0.000234	0.000442	CcSEcCtD
Topiramate—Insomnia—Fluorouracil—skin cancer	0.000232	0.000439	CcSEcCtD
Topiramate—Paraesthesia—Fluorouracil—skin cancer	0.000231	0.000436	CcSEcCtD
Topiramate—Alopecia—Docetaxel—skin cancer	0.000231	0.000436	CcSEcCtD
Topiramate—Feeling abnormal—Temozolomide—skin cancer	0.00023	0.000435	CcSEcCtD
Topiramate—Dyspnoea—Fluorouracil—skin cancer	0.000229	0.000433	CcSEcCtD
Topiramate—Mental disorder—Docetaxel—skin cancer	0.000229	0.000432	CcSEcCtD
Topiramate—Somnolence—Fluorouracil—skin cancer	0.000228	0.000432	CcSEcCtD
Topiramate—Gastrointestinal pain—Temozolomide—skin cancer	0.000228	0.000431	CcSEcCtD
Topiramate—Malnutrition—Docetaxel—skin cancer	0.000227	0.00043	CcSEcCtD
Topiramate—Erythema—Docetaxel—skin cancer	0.000227	0.00043	CcSEcCtD
Topiramate—Hypersensitivity—Dactinomycin—skin cancer	0.000227	0.00043	CcSEcCtD
Topiramate—Dyspepsia—Fluorouracil—skin cancer	0.000226	0.000428	CcSEcCtD
Topiramate—Decreased appetite—Fluorouracil—skin cancer	0.000223	0.000422	CcSEcCtD
Topiramate—Dysgeusia—Docetaxel—skin cancer	0.000223	0.000421	CcSEcCtD
Topiramate—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000222	0.000419	CcSEcCtD
Topiramate—Urticaria—Temozolomide—skin cancer	0.000222	0.000419	CcSEcCtD
Topiramate—Asthenia—Dactinomycin—skin cancer	0.000221	0.000418	CcSEcCtD
Topiramate—Body temperature increased—Temozolomide—skin cancer	0.00022	0.000417	CcSEcCtD
Topiramate—Abdominal pain—Temozolomide—skin cancer	0.00022	0.000417	CcSEcCtD
Topiramate—Back pain—Docetaxel—skin cancer	0.00022	0.000416	CcSEcCtD
Topiramate—Pain—Fluorouracil—skin cancer	0.00022	0.000415	CcSEcCtD
Topiramate—Muscle spasms—Docetaxel—skin cancer	0.000218	0.000413	CcSEcCtD
Topiramate—Feeling abnormal—Fluorouracil—skin cancer	0.000212	0.0004	CcSEcCtD
Topiramate—Diarrhoea—Dactinomycin—skin cancer	0.000211	0.000399	CcSEcCtD
Topiramate—Vomiting—Bleomycin—skin cancer	0.00021	0.000397	CcSEcCtD
Topiramate—Anaemia—Docetaxel—skin cancer	0.00021	0.000397	CcSEcCtD
Topiramate—Rash—Bleomycin—skin cancer	0.000208	0.000394	CcSEcCtD
Topiramate—Dermatitis—Bleomycin—skin cancer	0.000208	0.000394	CcSEcCtD
Topiramate—Hypersensitivity—Temozolomide—skin cancer	0.000205	0.000389	CcSEcCtD
Topiramate—Urticaria—Fluorouracil—skin cancer	0.000204	0.000386	CcSEcCtD
Topiramate—Syncope—Docetaxel—skin cancer	0.000204	0.000385	CcSEcCtD
Topiramate—Leukopenia—Docetaxel—skin cancer	0.000203	0.000385	CcSEcCtD
Topiramate—Body temperature increased—Fluorouracil—skin cancer	0.000203	0.000384	CcSEcCtD
Topiramate—SCN1A—L1CAM interactions—SCN10A—skin cancer	0.000202	0.0294	CbGpPWpGaD
Topiramate—Palpitations—Docetaxel—skin cancer	0.000201	0.00038	CcSEcCtD
Topiramate—Asthenia—Temozolomide—skin cancer	0.0002	0.000378	CcSEcCtD
Topiramate—Loss of consciousness—Docetaxel—skin cancer	0.0002	0.000378	CcSEcCtD
Topiramate—Cough—Docetaxel—skin cancer	0.000198	0.000375	CcSEcCtD
Topiramate—Pruritus—Temozolomide—skin cancer	0.000197	0.000373	CcSEcCtD
Topiramate—Convulsion—Docetaxel—skin cancer	0.000197	0.000372	CcSEcCtD
Topiramate—Nausea—Bleomycin—skin cancer	0.000196	0.000371	CcSEcCtD
Topiramate—Hypertension—Docetaxel—skin cancer	0.000196	0.000371	CcSEcCtD
Topiramate—Vomiting—Dactinomycin—skin cancer	0.000196	0.000371	CcSEcCtD
Topiramate—Rash—Dactinomycin—skin cancer	0.000194	0.000368	CcSEcCtD
Topiramate—Myalgia—Docetaxel—skin cancer	0.000193	0.000366	CcSEcCtD
Topiramate—Arthralgia—Docetaxel—skin cancer	0.000193	0.000366	CcSEcCtD
Topiramate—Chest pain—Docetaxel—skin cancer	0.000193	0.000366	CcSEcCtD
Topiramate—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000192	0.000363	CcSEcCtD
Topiramate—Diarrhoea—Temozolomide—skin cancer	0.000191	0.000361	CcSEcCtD
Topiramate—Hypersensitivity—Fluorouracil—skin cancer	0.000189	0.000358	CcSEcCtD
Topiramate—Dry mouth—Docetaxel—skin cancer	0.000189	0.000358	CcSEcCtD
Topiramate—Confusional state—Docetaxel—skin cancer	0.000187	0.000354	CcSEcCtD
Topiramate—Oedema—Docetaxel—skin cancer	0.000185	0.000351	CcSEcCtD
Topiramate—Dizziness—Temozolomide—skin cancer	0.000184	0.000349	CcSEcCtD
Topiramate—Infection—Docetaxel—skin cancer	0.000184	0.000348	CcSEcCtD
Topiramate—GRIA3—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—skin cancer	0.000183	0.0267	CbGpPWpGaD
Topiramate—Nausea—Dactinomycin—skin cancer	0.000183	0.000346	CcSEcCtD
Topiramate—Shock—Docetaxel—skin cancer	0.000182	0.000345	CcSEcCtD
Topiramate—Nervous system disorder—Docetaxel—skin cancer	0.000182	0.000344	CcSEcCtD
Topiramate—Pruritus—Fluorouracil—skin cancer	0.000182	0.000344	CcSEcCtD
Topiramate—Thrombocytopenia—Docetaxel—skin cancer	0.000182	0.000343	CcSEcCtD
Topiramate—Tachycardia—Docetaxel—skin cancer	0.000181	0.000342	CcSEcCtD
Topiramate—Skin disorder—Docetaxel—skin cancer	0.00018	0.000341	CcSEcCtD
Topiramate—Vomiting—Temozolomide—skin cancer	0.000177	0.000335	CcSEcCtD
Topiramate—Anorexia—Docetaxel—skin cancer	0.000177	0.000334	CcSEcCtD
Topiramate—Rash—Temozolomide—skin cancer	0.000176	0.000332	CcSEcCtD
Topiramate—Diarrhoea—Fluorouracil—skin cancer	0.000176	0.000332	CcSEcCtD
Topiramate—Dermatitis—Temozolomide—skin cancer	0.000176	0.000332	CcSEcCtD
Topiramate—Headache—Temozolomide—skin cancer	0.000175	0.00033	CcSEcCtD
Topiramate—Hypotension—Docetaxel—skin cancer	0.000173	0.000328	CcSEcCtD
Topiramate—Dizziness—Fluorouracil—skin cancer	0.00017	0.000321	CcSEcCtD
Topiramate—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000169	0.000319	CcSEcCtD
Topiramate—Insomnia—Docetaxel—skin cancer	0.000168	0.000317	CcSEcCtD
Topiramate—Paraesthesia—Docetaxel—skin cancer	0.000167	0.000315	CcSEcCtD
Topiramate—Nausea—Temozolomide—skin cancer	0.000166	0.000313	CcSEcCtD
Topiramate—Dyspnoea—Docetaxel—skin cancer	0.000165	0.000313	CcSEcCtD
Topiramate—Somnolence—Docetaxel—skin cancer	0.000165	0.000312	CcSEcCtD
Topiramate—Vomiting—Fluorouracil—skin cancer	0.000163	0.000309	CcSEcCtD
Topiramate—Dyspepsia—Docetaxel—skin cancer	0.000163	0.000309	CcSEcCtD
Topiramate—Rash—Fluorouracil—skin cancer	0.000162	0.000306	CcSEcCtD
Topiramate—Dermatitis—Fluorouracil—skin cancer	0.000162	0.000306	CcSEcCtD
Topiramate—Decreased appetite—Docetaxel—skin cancer	0.000161	0.000305	CcSEcCtD
Topiramate—Headache—Fluorouracil—skin cancer	0.000161	0.000304	CcSEcCtD
Topiramate—Gastrointestinal disorder—Docetaxel—skin cancer	0.00016	0.000303	CcSEcCtD
Topiramate—Fatigue—Docetaxel—skin cancer	0.00016	0.000302	CcSEcCtD
Topiramate—Pain—Docetaxel—skin cancer	0.000159	0.0003	CcSEcCtD
Topiramate—Constipation—Docetaxel—skin cancer	0.000159	0.0003	CcSEcCtD
Topiramate—Feeling abnormal—Docetaxel—skin cancer	0.000153	0.000289	CcSEcCtD
Topiramate—Nausea—Fluorouracil—skin cancer	0.000153	0.000289	CcSEcCtD
Topiramate—Gastrointestinal pain—Docetaxel—skin cancer	0.000152	0.000287	CcSEcCtD
Topiramate—Body temperature increased—Docetaxel—skin cancer	0.000147	0.000277	CcSEcCtD
Topiramate—Abdominal pain—Docetaxel—skin cancer	0.000147	0.000277	CcSEcCtD
Topiramate—SCN5A—L1CAM interactions—SCN10A—skin cancer	0.000142	0.0207	CbGpPWpGaD
Topiramate—Hypersensitivity—Docetaxel—skin cancer	0.000137	0.000258	CcSEcCtD
Topiramate—Asthenia—Docetaxel—skin cancer	0.000133	0.000252	CcSEcCtD
Topiramate—Pruritus—Docetaxel—skin cancer	0.000131	0.000248	CcSEcCtD
Topiramate—Diarrhoea—Docetaxel—skin cancer	0.000127	0.00024	CcSEcCtD
Topiramate—Dizziness—Docetaxel—skin cancer	0.000123	0.000232	CcSEcCtD
Topiramate—GRIK5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	0.00012	0.0174	CbGpPWpGaD
Topiramate—GRIK4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	0.00012	0.0174	CbGpPWpGaD
Topiramate—Vomiting—Docetaxel—skin cancer	0.000118	0.000223	CcSEcCtD
Topiramate—Rash—Docetaxel—skin cancer	0.000117	0.000221	CcSEcCtD
Topiramate—Dermatitis—Docetaxel—skin cancer	0.000117	0.000221	CcSEcCtD
Topiramate—Headache—Docetaxel—skin cancer	0.000116	0.00022	CcSEcCtD
Topiramate—GRIA4—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—skin cancer	0.000116	0.0169	CbGpPWpGaD
Topiramate—GRIK3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	0.000111	0.0162	CbGpPWpGaD
Topiramate—GRIK1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	0.000111	0.0162	CbGpPWpGaD
Topiramate—Nausea—Docetaxel—skin cancer	0.00011	0.000208	CcSEcCtD
Topiramate—GRIA1—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—skin cancer	0.00011	0.016	CbGpPWpGaD
Topiramate—GRIA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	9.45e-05	0.0137	CbGpPWpGaD
Topiramate—GRIK5—Transmission across Chemical Synapses—BRAF—skin cancer	8.99e-05	0.0131	CbGpPWpGaD
Topiramate—GRIK4—Transmission across Chemical Synapses—BRAF—skin cancer	8.99e-05	0.0131	CbGpPWpGaD
Topiramate—GRIA3—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—skin cancer	8.43e-05	0.0123	CbGpPWpGaD
Topiramate—GRIK1—Transmission across Chemical Synapses—BRAF—skin cancer	8.36e-05	0.0122	CbGpPWpGaD
Topiramate—GRIK3—Transmission across Chemical Synapses—BRAF—skin cancer	8.36e-05	0.0122	CbGpPWpGaD
Topiramate—GRIA2—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—skin cancer	7.69e-05	0.0112	CbGpPWpGaD
Topiramate—SCN1A—Axon guidance—SCN10A—skin cancer	7.65e-05	0.0111	CbGpPWpGaD
Topiramate—CA9—HIF-1-alpha transcription factor network—TERT—skin cancer	7.31e-05	0.0106	CbGpPWpGaD
Topiramate—GRIA4—Transmission across Chemical Synapses—BRAF—skin cancer	7.11e-05	0.0103	CbGpPWpGaD
Topiramate—GRIK4—Neuronal System—BRAF—skin cancer	6.89e-05	0.01	CbGpPWpGaD
Topiramate—GRIK5—Neuronal System—BRAF—skin cancer	6.89e-05	0.01	CbGpPWpGaD
Topiramate—GRIA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	6.87e-05	0.00999	CbGpPWpGaD
Topiramate—GRIK1—Neuronal System—BRAF—skin cancer	6.4e-05	0.00931	CbGpPWpGaD
Topiramate—GRIK3—Neuronal System—BRAF—skin cancer	6.4e-05	0.00931	CbGpPWpGaD
Topiramate—GRIA1—Amyotrophic lateral sclerosis (ALS)—TP53—skin cancer	5.61e-05	0.00816	CbGpPWpGaD
Topiramate—GRIK5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	5.5e-05	0.00799	CbGpPWpGaD
Topiramate—GRIK4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	5.5e-05	0.00799	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—SCN10A—skin cancer	5.46e-05	0.00794	CbGpPWpGaD
Topiramate—GRIA4—Neuronal System—BRAF—skin cancer	5.44e-05	0.00792	CbGpPWpGaD
Topiramate—SCN5A—Axon guidance—SCN10A—skin cancer	5.38e-05	0.00782	CbGpPWpGaD
Topiramate—GRIA3—Transmission across Chemical Synapses—BRAF—skin cancer	5.16e-05	0.00751	CbGpPWpGaD
Topiramate—GRIK1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	5.11e-05	0.00743	CbGpPWpGaD
Topiramate—GRIK3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	5.11e-05	0.00743	CbGpPWpGaD
Topiramate—GRIA1—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—skin cancer	5.05e-05	0.00735	CbGpPWpGaD
Topiramate—CA1—C-MYB transcription factor network—CDKN2A—skin cancer	4.69e-05	0.00682	CbGpPWpGaD
Topiramate—SCN1A—Axon guidance—RASA1—skin cancer	4.39e-05	0.00639	CbGpPWpGaD
Topiramate—CA1—C-MYB transcription factor network—PTGS2—skin cancer	4.39e-05	0.00638	CbGpPWpGaD
Topiramate—GRIA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	4.35e-05	0.00632	CbGpPWpGaD
Topiramate—GRIK4—Transmission across Chemical Synapses—HRAS—skin cancer	4.13e-05	0.00601	CbGpPWpGaD
Topiramate—GRIK5—Transmission across Chemical Synapses—HRAS—skin cancer	4.13e-05	0.00601	CbGpPWpGaD
Topiramate—GRIA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	4.11e-05	0.00598	CbGpPWpGaD
Topiramate—GRIA3—Neuronal System—BRAF—skin cancer	3.96e-05	0.00575	CbGpPWpGaD
Topiramate—GRIK3—Transmission across Chemical Synapses—HRAS—skin cancer	3.84e-05	0.00559	CbGpPWpGaD
Topiramate—GRIK1—Transmission across Chemical Synapses—HRAS—skin cancer	3.84e-05	0.00559	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—SCN10A—skin cancer	3.84e-05	0.00558	CbGpPWpGaD
Topiramate—GRIK2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	3.76e-05	0.00547	CbGpPWpGaD
Topiramate—GRIA2—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—skin cancer	3.53e-05	0.00514	CbGpPWpGaD
Topiramate—CA5A—Metabolism—PLIN2—skin cancer	3.49e-05	0.00508	CbGpPWpGaD
Topiramate—CA6—Metabolism—PLIN2—skin cancer	3.49e-05	0.00508	CbGpPWpGaD
Topiramate—CA1—C-MYB transcription factor network—NRAS—skin cancer	3.41e-05	0.00496	CbGpPWpGaD
Topiramate—GRIA4—Transmission across Chemical Synapses—HRAS—skin cancer	3.27e-05	0.00475	CbGpPWpGaD
Topiramate—CA5B—Metabolism—PLIN2—skin cancer	3.26e-05	0.00474	CbGpPWpGaD
Topiramate—CA7—Metabolism—PLIN2—skin cancer	3.26e-05	0.00474	CbGpPWpGaD
Topiramate—GRIK4—Neuronal System—HRAS—skin cancer	3.17e-05	0.00461	CbGpPWpGaD
Topiramate—GRIK5—Neuronal System—HRAS—skin cancer	3.17e-05	0.00461	CbGpPWpGaD
Topiramate—GRIA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	3.16e-05	0.00459	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—RASA1—skin cancer	3.14e-05	0.00456	CbGpPWpGaD
Topiramate—GRIA1—Transmission across Chemical Synapses—BRAF—skin cancer	3.09e-05	0.0045	CbGpPWpGaD
Topiramate—SCN5A—Axon guidance—RASA1—skin cancer	3.09e-05	0.00449	CbGpPWpGaD
Topiramate—GRIA3—BDNF signaling pathway—HRAS—skin cancer	3.09e-05	0.00449	CbGpPWpGaD
Topiramate—CA12—Metabolism—PLIN2—skin cancer	3.02e-05	0.00439	CbGpPWpGaD
Topiramate—GRIK1—Neuronal System—HRAS—skin cancer	2.94e-05	0.00428	CbGpPWpGaD
Topiramate—GRIK3—Neuronal System—HRAS—skin cancer	2.94e-05	0.00428	CbGpPWpGaD
Topiramate—CA1—C-MYB transcription factor network—KRAS—skin cancer	2.94e-05	0.00427	CbGpPWpGaD
Topiramate—GRIA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	2.88e-05	0.00418	CbGpPWpGaD
Topiramate—GRIK2—Transmission across Chemical Synapses—BRAF—skin cancer	2.83e-05	0.00411	CbGpPWpGaD
Topiramate—CA5A—Metabolism—CSPG4—skin cancer	2.82e-05	0.0041	CbGpPWpGaD
Topiramate—CA6—Metabolism—CSPG4—skin cancer	2.82e-05	0.0041	CbGpPWpGaD
Topiramate—GABRB2—Transmembrane transport of small molecules—SLC12A2—skin cancer	2.69e-05	0.00391	CbGpPWpGaD
Topiramate—CA5B—Metabolism—CSPG4—skin cancer	2.63e-05	0.00382	CbGpPWpGaD
Topiramate—CA7—Metabolism—CSPG4—skin cancer	2.63e-05	0.00382	CbGpPWpGaD
Topiramate—GRIA4—Neuronal System—HRAS—skin cancer	2.5e-05	0.00364	CbGpPWpGaD
Topiramate—CA1—C-MYB transcription factor network—HRAS—skin cancer	2.5e-05	0.00363	CbGpPWpGaD
Topiramate—GABRG2—Transmembrane transport of small molecules—SLC12A2—skin cancer	2.46e-05	0.00357	CbGpPWpGaD
Topiramate—CA12—Metabolism—CSPG4—skin cancer	2.44e-05	0.00354	CbGpPWpGaD
Topiramate—CA4—Metabolism—PLIN2—skin cancer	2.41e-05	0.0035	CbGpPWpGaD
Topiramate—GRIA3—Transmission across Chemical Synapses—HRAS—skin cancer	2.37e-05	0.00345	CbGpPWpGaD
Topiramate—GRIA1—Neuronal System—BRAF—skin cancer	2.37e-05	0.00345	CbGpPWpGaD
Topiramate—CA2—Metabolism—PLIN2—skin cancer	2.31e-05	0.00336	CbGpPWpGaD
Topiramate—CA1—Metabolism—PLIN2—skin cancer	2.21e-05	0.00322	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—RASA1—skin cancer	2.2e-05	0.00321	CbGpPWpGaD
Topiramate—GRIK2—Neuronal System—BRAF—skin cancer	2.17e-05	0.00315	CbGpPWpGaD
Topiramate—GRIA2—Transmission across Chemical Synapses—BRAF—skin cancer	2.16e-05	0.00315	CbGpPWpGaD
Topiramate—GABRB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	2.16e-05	0.00314	CbGpPWpGaD
Topiramate—CA9—Cellular responses to stress—CDK4—skin cancer	2.16e-05	0.00314	CbGpPWpGaD
Topiramate—GABRA1—Transmembrane transport of small molecules—SLC12A2—skin cancer	2.15e-05	0.00312	CbGpPWpGaD
Topiramate—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	1.98e-05	0.00287	CbGpPWpGaD
Topiramate—CA9—Metabolism—PLIN2—skin cancer	1.95e-05	0.00283	CbGpPWpGaD
Topiramate—CA4—Metabolism—CSPG4—skin cancer	1.94e-05	0.00282	CbGpPWpGaD
Topiramate—CA5A—Metabolism—ENO2—skin cancer	1.91e-05	0.00278	CbGpPWpGaD
Topiramate—CA6—Metabolism—ENO2—skin cancer	1.91e-05	0.00278	CbGpPWpGaD
Topiramate—GRIA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	1.89e-05	0.00275	CbGpPWpGaD
Topiramate—CA2—Metabolism—CSPG4—skin cancer	1.86e-05	0.00271	CbGpPWpGaD
Topiramate—GRIA1—BDNF signaling pathway—HRAS—skin cancer	1.85e-05	0.00269	CbGpPWpGaD
Topiramate—GRIA3—Neuronal System—HRAS—skin cancer	1.82e-05	0.00264	CbGpPWpGaD
Topiramate—CA5B—Metabolism—ENO2—skin cancer	1.79e-05	0.0026	CbGpPWpGaD
Topiramate—CA7—Metabolism—ENO2—skin cancer	1.79e-05	0.0026	CbGpPWpGaD
Topiramate—CA1—Metabolism—CSPG4—skin cancer	1.79e-05	0.0026	CbGpPWpGaD
Topiramate—GRIK2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	1.73e-05	0.00252	CbGpPWpGaD
Topiramate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	1.73e-05	0.00251	CbGpPWpGaD
Topiramate—GRIA2—Neuronal System—BRAF—skin cancer	1.66e-05	0.00241	CbGpPWpGaD
Topiramate—CA12—Metabolism—ENO2—skin cancer	1.66e-05	0.00241	CbGpPWpGaD
Topiramate—CA9—Cellular responses to stress—CDKN2A—skin cancer	1.65e-05	0.0024	CbGpPWpGaD
Topiramate—CYP2C19—Arachidonic acid metabolism—PTGS2—skin cancer	1.63e-05	0.00238	CbGpPWpGaD
Topiramate—GABRB2—Transmission across Chemical Synapses—BRAF—skin cancer	1.62e-05	0.00236	CbGpPWpGaD
Topiramate—CA9—Metabolism—CSPG4—skin cancer	1.57e-05	0.00228	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—CDK4—skin cancer	1.54e-05	0.00224	CbGpPWpGaD
Topiramate—GABRG2—Transmission across Chemical Synapses—BRAF—skin cancer	1.49e-05	0.00216	CbGpPWpGaD
Topiramate—GRIA1—Transmission across Chemical Synapses—HRAS—skin cancer	1.42e-05	0.00207	CbGpPWpGaD
Topiramate—GRIA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	1.32e-05	0.00192	CbGpPWpGaD
Topiramate—CA4—Metabolism—ENO2—skin cancer	1.32e-05	0.00192	CbGpPWpGaD
Topiramate—GRIK2—Transmission across Chemical Synapses—HRAS—skin cancer	1.3e-05	0.00189	CbGpPWpGaD
Topiramate—GABRA1—Transmission across Chemical Synapses—BRAF—skin cancer	1.3e-05	0.00189	CbGpPWpGaD
Topiramate—GRIA2—BDNF signaling pathway—HRAS—skin cancer	1.29e-05	0.00188	CbGpPWpGaD
Topiramate—CA2—Metabolism—ENO2—skin cancer	1.27e-05	0.00184	CbGpPWpGaD
Topiramate—GABRB2—Neuronal System—BRAF—skin cancer	1.24e-05	0.00181	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	1.22e-05	0.00178	CbGpPWpGaD
Topiramate—CA1—Metabolism—ENO2—skin cancer	1.21e-05	0.00176	CbGpPWpGaD
Topiramate—SCN1A—Axon guidance—NRAS—skin cancer	1.2e-05	0.00174	CbGpPWpGaD
Topiramate—GABRG2—Neuronal System—BRAF—skin cancer	1.14e-05	0.00166	CbGpPWpGaD
Topiramate—CA5A—Metabolism—ERCC2—skin cancer	1.11e-05	0.00162	CbGpPWpGaD
Topiramate—CA6—Metabolism—ERCC2—skin cancer	1.11e-05	0.00162	CbGpPWpGaD
Topiramate—GRIA1—Neuronal System—HRAS—skin cancer	1.09e-05	0.00158	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—CDK4—skin cancer	1.08e-05	0.00157	CbGpPWpGaD
Topiramate—CA9—Metabolism—ENO2—skin cancer	1.07e-05	0.00155	CbGpPWpGaD
Topiramate—SCN5A—SIDS Susceptibility Pathways—IL6—skin cancer	1.06e-05	0.00154	CbGpPWpGaD
Topiramate—CA7—Metabolism—ERCC2—skin cancer	1.04e-05	0.00151	CbGpPWpGaD
Topiramate—CA5B—Metabolism—ERCC2—skin cancer	1.04e-05	0.00151	CbGpPWpGaD
Topiramate—SCN1A—Axon guidance—KRAS—skin cancer	1.03e-05	0.0015	CbGpPWpGaD
Topiramate—GRIK2—Neuronal System—HRAS—skin cancer	9.97e-06	0.00145	CbGpPWpGaD
Topiramate—GABRA1—Neuronal System—BRAF—skin cancer	9.95e-06	0.00145	CbGpPWpGaD
Topiramate—GRIA2—Transmission across Chemical Synapses—HRAS—skin cancer	9.95e-06	0.00145	CbGpPWpGaD
Topiramate—GABRB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	9.94e-06	0.00145	CbGpPWpGaD
Topiramate—CA12—Metabolism—ERCC2—skin cancer	9.62e-06	0.0014	CbGpPWpGaD
Topiramate—CA9—Cellular responses to stress—TP53—skin cancer	9.18e-06	0.00133	CbGpPWpGaD
Topiramate—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	9.09e-06	0.00132	CbGpPWpGaD
Topiramate—SCN1A—Axon guidance—HRAS—skin cancer	8.76e-06	0.00127	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—NRAS—skin cancer	8.55e-06	0.00124	CbGpPWpGaD
Topiramate—SCN5A—Axon guidance—NRAS—skin cancer	8.42e-06	0.00122	CbGpPWpGaD
Topiramate—CA9—Cellular responses to stress—IL6—skin cancer	8.4e-06	0.00122	CbGpPWpGaD
Topiramate—SCN1A—Axon guidance—IL6—skin cancer	8.39e-06	0.00122	CbGpPWpGaD
Topiramate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	7.94e-06	0.00116	CbGpPWpGaD
Topiramate—CA4—Metabolism—ERCC2—skin cancer	7.67e-06	0.00112	CbGpPWpGaD
Topiramate—GRIA2—Neuronal System—HRAS—skin cancer	7.62e-06	0.00111	CbGpPWpGaD
Topiramate—GABRB2—Transmission across Chemical Synapses—HRAS—skin cancer	7.47e-06	0.00109	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—KRAS—skin cancer	7.36e-06	0.00107	CbGpPWpGaD
Topiramate—CA2—Metabolism—ERCC2—skin cancer	7.35e-06	0.00107	CbGpPWpGaD
Topiramate—SCN5A—Axon guidance—KRAS—skin cancer	7.25e-06	0.00105	CbGpPWpGaD
Topiramate—CA1—Metabolism—ERCC2—skin cancer	7.05e-06	0.00103	CbGpPWpGaD
Topiramate—GABRA1—SIDS Susceptibility Pathways—IL6—skin cancer	6.97e-06	0.00101	CbGpPWpGaD
Topiramate—GABRG2—Transmission across Chemical Synapses—HRAS—skin cancer	6.83e-06	0.000994	CbGpPWpGaD
Topiramate—CA6—Metabolism—PTGS2—skin cancer	6.67e-06	0.00097	CbGpPWpGaD
Topiramate—CA5A—Metabolism—PTGS2—skin cancer	6.67e-06	0.00097	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—HRAS—skin cancer	6.25e-06	0.00091	CbGpPWpGaD
Topiramate—CA7—Metabolism—PTGS2—skin cancer	6.22e-06	0.000905	CbGpPWpGaD
Topiramate—CA5B—Metabolism—PTGS2—skin cancer	6.22e-06	0.000905	CbGpPWpGaD
Topiramate—CA9—Metabolism—ERCC2—skin cancer	6.2e-06	0.000901	CbGpPWpGaD
Topiramate—SCN5A—Axon guidance—HRAS—skin cancer	6.16e-06	0.000896	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—NRAS—skin cancer	6.01e-06	0.000874	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—IL6—skin cancer	5.99e-06	0.000871	CbGpPWpGaD
Topiramate—GABRA1—Transmission across Chemical Synapses—HRAS—skin cancer	5.97e-06	0.000868	CbGpPWpGaD
Topiramate—SCN5A—Axon guidance—IL6—skin cancer	5.9e-06	0.000858	CbGpPWpGaD
Topiramate—CA12—Metabolism—PTGS2—skin cancer	5.77e-06	0.000839	CbGpPWpGaD
Topiramate—GABRB2—Neuronal System—HRAS—skin cancer	5.72e-06	0.000832	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—PLIN2—skin cancer	5.45e-06	0.000793	CbGpPWpGaD
Topiramate—GABRG2—Neuronal System—HRAS—skin cancer	5.24e-06	0.000761	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—KRAS—skin cancer	5.17e-06	0.000752	CbGpPWpGaD
Topiramate—CA4—Metabolism—PTGS2—skin cancer	4.6e-06	0.000669	CbGpPWpGaD
Topiramate—GABRA1—Neuronal System—HRAS—skin cancer	4.58e-06	0.000665	CbGpPWpGaD
Topiramate—CA2—Metabolism—PTGS2—skin cancer	4.41e-06	0.000641	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—HRAS—skin cancer	4.4e-06	0.000639	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—CSPG4—skin cancer	4.39e-06	0.000639	CbGpPWpGaD
Topiramate—CA1—Metabolism—PTGS2—skin cancer	4.23e-06	0.000615	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—IL6—skin cancer	4.21e-06	0.000612	CbGpPWpGaD
Topiramate—CA9—Metabolism—PTGS2—skin cancer	3.72e-06	0.00054	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—PLIN2—skin cancer	3.28e-06	0.000477	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—ENO2—skin cancer	2.99e-06	0.000434	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—CSPG4—skin cancer	2.64e-06	0.000384	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	2.34e-06	0.00034	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—ENO2—skin cancer	1.8e-06	0.000261	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—ERCC2—skin cancer	1.73e-06	0.000252	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—ERCC2—skin cancer	1.04e-06	0.000152	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—PTGS2—skin cancer	1.04e-06	0.000151	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—PTGS2—skin cancer	6.26e-07	9.1e-05	CbGpPWpGaD
